Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2007

01-03-2007 | LETTER TO THE EDITOR

Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results

Authors: Adriana V Roehe, Ana Paula G Frazzon, Grasiela Agnes, Andrea P Damin, Antonio A Hartman, Marcia S Graudenz

Published in: Breast Cancer Research and Treatment | Issue 1/2007

Login to get access
Metadata
Title
Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results
Authors
Adriana V Roehe
Ana Paula G Frazzon
Grasiela Agnes
Andrea P Damin
Antonio A Hartman
Marcia S Graudenz
Publication date
01-03-2007
Published in
Breast Cancer Research and Treatment / Issue 1/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9273-1

Other articles of this Issue 1/2007

Breast Cancer Research and Treatment 1/2007 Go to the issue

Epidemiology

A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland

Preclinical study

Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo

Preclinical Study

Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines

Clinical Trial

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

Preclinical Study

Legumain expression as a prognostic factor in breast cancer patients

Epidemiology

Variants in estrogen metabolism and biosynthesis genes and urinary estrogen metabolites in women with a family history of breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits